HONOLULU, Nov. 7 /PRNewswire/ -- Tissue Genesis, Inc. announced an exclusive distribution and licensing agreement for the human spine market with SpineSmith Partners, LP (Austin, Texas). Tissue Genesis will share SpineSmith's revenues from procedures and sales using Tissue Genesis' therapeutic cell technologies, and expects in the future to receive revenue from sales to SpineSmith of TGI 1000(TM) cell isolation systems and disposables, over the four year term of the agreement. Additionally, SpineSmith has been granted the rights to manufacture, use and sell TGI 100(TM) manual cell isolation kits, incorporating Tissue Genesis supplied Adipase(TM) enzyme solution.
"This exciting new relationship with SpineSmith allows Tissue Genesis to move our therapeutic cell technologies into orthopedic markets," said Anton C. Krucky, President and CEO of Tissue Genesis. "SpineSmith's extensive expertise with bone marrow stem cells, in both cell isolation and medical insurance reimbursement, provides a clear avenue of advancement of our adipose (fat) derived stem cells into this important market."
"SpineSmith has been involved in the treatment of spine injuries for over two years, having provided bone marrow derived, autologous (the patient's own) stem cells to over three thousand patients," said Kevin Dunworth, founder of SpineSmith. "We believe stem cells to be the next frontier in spine surgery and the Tissue Genesis cell isolation system rapidly processes a small quantity of a patient's own fat tissue to produce large quantities of cells, including adult stem cells and microvascular cells."
Tissue Genesis, Inc.
Tissue Genesis, Inc. (http://www.tissuegenesis.com) is a Qualified High
Technology Business (QHTB) in Honolulu, Hawaii that is seeking to develop
innovative tissue engineering solutions and technology to address a range
of therapeutic areas including vascular, cardiovascular, orthoped
|SOURCE Tissue Genesis, Inc.|
Copyright©2007 PR Newswire.
All rights reserved